Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Immunotherapy could revolutionize cancer care by developing nontoxic, highly efficient and decisive cures that do not rely on chemotherapeutic agents. These treatments could be used in 60% of advanced cancer patients by 2025. Canada needs greater capacity to translate these therapies into patient care, and to help companies compete in a potential $40 billion market.
C3i (Centre for Commercialisation of Cancer Immunotherapy) will accelerate access to innovative cancer immunotherapies for patients. Operating out of the Hôpital Maisonneuve- Rosemont in Montreal, Canada, C3i offers an integrated structure for the development, translation and commercialization of these ground breaking therapies. Our 37,000 sqf cGMP Manufacturing unit comprising 14 clean rooms is open to biotech and pharma companies willing to manufacture their Cell and Gene Therapies in a Canadian state-of-the-art cGMP facility.